Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 8Prostatic Neoplasms 7Ovarian Neoplasms 6Breast Neoplasms 6Carcinoma, Transitional Cell 5Stomach Neoplasms 4Pancreatic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Neoplasms 3Neoplasm Metastasis 3Esophageal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Wilms Tumor 1Uterine Cervical Neoplasms 1Tumor Virus Infections 1Thrombocytosis 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrent Bladder Urothelial Carcinoma 1Recurrence 1

Interventions

pembrolizumab 4spartalizumab 2Nivolumab 2tislelizumab 1obinutuzumab 1naptumomab estafenatox 1durvalumab 1brivanib 1abemaciclib 1Gemcitabine 1Cisplatin 1Carboplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Albumin-Bound Paclitaxel × Genitourinary × Clear all
NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Gossamer Bio Inc.

Phase 1 Terminated
61 enrolled
BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡